Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 2019American Journal of HematologyOpen Access

Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

IAIbrahim AldossCity of HopeDYDongyun YangCity Of Hope National Medical CenterRPRaju PillaiCity Of Hope National Medical Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Aldoss et al. (2019) studied this question.

synapsesocial.com/papers/6a70433fac440176ef28e88bhttps://doi.org/10.1002/ajh.25567
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia2018 · 1,893 citations
  2. 2Genomics of Acute Myeloid Leukemia Diagnosis and Pathways2017 · 602 citations
  3. 3TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients2014 · 568 citations
  4. 4DNMT3A Mutations in Acute Myeloid Leukemia2010 · 2,009 citations
  5. 5Clinical and biological implications of driver mutations in myelodysplastic syndromes2013 · 1,869 citations